Amikacin Inhale Shows Promising Results in Phas...(rm them to future events ordevelopments....),Health

Nektar - This press release contains forward-looking statements regarding the potential and clinical development plans for Amikacin Inhale. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's or its partners' clinical trials may fail to meet minimum clinical end points; (ii) Nektar or its partners may ultimately fail to obtain regulatory approval of one or more product candidates; and (iii) the timing or success of commencing or concluding clinical trials is subject to a number of risks uncertainties including but not limited to clinical trial design, patient enrollment, regulatory requirements, manufacturing scale-up and clinical outcomes. These forward-looking statements involve substantial risks and uncertainties, including those risks and uncertainties that are detailed in Nektar's reports and other filings with the SEC including its most recent Quarterly Report on Form 10-Q filed on May 9, 2008. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise. No information regarding or presented at the medical and scientific meetings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release.

(1) Chastre J & Fagon J-Y. Am J Respir Crit Care Med 2002;165:867-903

(2) Corkery K, et al. Evidence of High Amikacin Lung Deposition in

Mechanically Ventilated Patients (MVP) with Pneumonia and Healthy

Subjects (HS) dosed using NKTR-061. Poster 517 American Thoracic

Society International Conference, May 19, 2008

(3) Santre C. Georges H, Jacquier JM, Leroy O , Beuscart C, Buguin D,

Beaucarie G et al, Amikacin levels in bronchial secretions of 10

'/>"/>